Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 17, 22 | -0.30
Decreased by
-151.72%
|
-0.36
Increased by
+16.67%
|
Nov 14, 22 | -0.30
Increased by
+43.40%
|
-0.36
Increased by
+16.67%
|
Aug 15, 22 | -0.30
Increased by
+48.28%
|
-0.46
Increased by
+34.78%
|
May 16, 22 | -0.48
Increased by
+69.23%
|
-0.43
Decreased by
-11.63%
|
Mar 30, 22 | 0.58
Increased by
+130.53%
|
-0.62
Increased by
+193.55%
|
Nov 12, 21 | -0.53 | -0.72
Increased by
+26.39%
|
Aug 12, 21 | -0.58 | -0.69
Increased by
+15.94%
|
May 17, 21 | -1.56 | -0.62
Decreased by
-151.61%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
-100.00%
|
-8.99 M
Increased by
+42.77%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 653.00 K
Increased by
+20.93%
|
-9.14 M
Increased by
+46.47%
|
Decreased by
-1.40 K%
Increased by
+55.73%
|
Mar 31, 22 | 1.65 M
Increased by
+344.20%
|
-14.24 M
Increased by
+61.19%
|
Decreased by
-864.08%
Increased by
+91.26%
|
Dec 31, 21 | 25.94 M
Increased by
+5.55 K%
|
14.89 M
Increased by
+151.57%
|
Increased by
+57.40%
Increased by
+100.91%
|
Sep 30, 21 | 1.46 M
Increased by
+76.54%
|
-15.70 M
Increased by
+11.12%
|
Decreased by
-1.08 K%
Increased by
+49.66%
|
Jun 30, 21 | 540.00 K
Decreased by
-25.93%
|
-17.07 M
Increased by
+16.07%
|
Decreased by
-3.16 K%
Decreased by
-13.30%
|
Mar 31, 21 | 371.00 K
Decreased by
-57.11%
|
-36.69 M
Decreased by
-177.47%
|
Decreased by
-9.89 K%
Decreased by
-546.93%
|
Dec 31, 20 | 459.00 K
Decreased by
-34.05%
|
-28.88 M
Decreased by
-80.30%
|
Decreased by
-6.29 K%
Decreased by
-173.40%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.